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A B S T R A C T
Purpose
Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC) who have adenocarcino-
ma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of
erlotinib alone or in combination with chemotherapy in patients with these characteristics.
Patients and Methods
Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor
tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of  100
cigarettes and  10 pack years and quit  1 year ago) were randomly assigned to contin-
uous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by
erlotinib alone. The primary end point was progression-free survival (PFS). Tissue collection
was mandatory.
Results
PFS was similar (5.0 v 6.6 months; P  .1988) in patients randomly assigned to erlotinib alone (arm
A; n  81) or to ECP (arm B; n  100). EGFR mutation analysis was possible in 91% (164 of 181)
of patients, and EGFR mutations were detected in 40% (51 of 128) of never smokers and in 42%
(15 of 36) of light former smokers. In arm A, response rate (70% v 9%), PFS (14.1 v 2.6 months),
and overall survival (OS; 31.3 v 18.1 month) favored EGFR-mutant patients. In arm B, response
rate (73% v 30%), PFS (17.2 v 4.8 months), and OS (38.1 v 14.4 months) favored EGFR-mutant
patients. Incidence of grades 3 to 4 hematologic (2% v 49%; P  .001) and nonhematologic (24%
v 52%; P  .001) toxicity was greater in patients treated with ECP.
Conclusion
Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of
patients with advanced NSCLC. EGFR mutations identify patients most likely to benefit.
J Clin Oncol 30:2063-2069. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is the leading cause of cancer mortality
in the United States and in the world, and more than
85% of patients with lung cancer have non–small-
cell lung cancer (NSCLC).1 A majority of patients
with lung cancer have stage IIIB or IV disease at the
time of diagnosis, and palliative therapy with
platinum-based double-agent chemotherapy is the
standard therapy.2 The epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitor (TKI) erlo-
tinib is an effective treatment for patients with
NSCLC for whom systemic chemotherapy has
failed.3 The efficacy of EGFR TKIs, including erlo-
tinib, is greatest in the subset of patients with
NSCLC who are never or limited former cigarette
smokers.3 This is likely because of the higher fre-
quency of somatic mutations in the EGFR kinase
domain in this phenotypic subset of patients with
NSCLC.4,5 This observation has been confirmed in
prospective clinical trials.6
A phase III trial evaluated the role of adding
erlotinibtofirst-linecarboplatinandpaclitaxelchem-
otherapy in patients with advanced NSCLC.7 This
strategy did not result in improvement in re-
sponse rate (RR), time to progression, or overall
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survival (OS) in the intent-to-treat patient population.7 However,
a subset analysis of patients who were never smokers revealed
significant improvement in RR (30% v 11%; P  .02), time to
progression (hazard ratio [HR], 0.50; 95% CI, 0.31 to 0.80; median,
6.0 and 4.3 months, respectively), and OS (HR, 0.49; 95% CI, 0.28
to 0.85; median, 22.5 and 10.1 months, respectively) for those
treated in the erlotinib-containing arm compared with the chemo-
therapy and placebo arms.7 One potential reason for this clinical
observation is a combined benefit of chemotherapy and erlotinib in
the subset of patients likely to benefit from erlotinib therapy. Alterna-
tively, the outcome differences may have been solely the result of
increased efficacy of erlotinib in never smokers and/or in patients with
EGFR-mutant advanced NSCLC.3 We thus developed a randomized
phase II trial to investigate the efficacy of erlotinib alone and in com-
bination with chemotherapy in patients selected based on clinical
characteristics associated with known erlotinib benefit. At the time
this trial was developed, routine EGFR mutation testing was not
available. However, because of an interest in investigating the
impact of EGFR mutations on the outcome of erlotinib-based
therapy, tissue submission and specific tissue requirements were
part of the trial eligibility.
PATIENTS AND METHODS
Eligibility Criteria
Patients were required to have histologic documentation of primary lung
adenocarcinoma; patients with bronchioloaveolar or adenosquamous carci-
noma were eligible. Patients were required to have at least a core biopsy and be
a never smoker (defined as smoking  100 cigarettes in lifetime) or former
light smoker (defined as smoking  100 cigarettes and  10 pack years and
quit  1 year ago). Other eligibility criteria were stage IIIB disease with
malignant pleural or pericardial effusion or stage IV disease, age  18 years,
Eastern Cooperative Oncology Group performance status of 0 or 1, and
measureable disease as defined by RECIST (Response Evaluation Criteria for
Solid Tumors).8 Laboratory requirements were an absolute neutrophil
count  1,500/mL, platelet count  100,000/mL, hemoglobin  9.0 g/dL,
renal function  1.5 mg/dL, total bilirubin less than upper limit of normal, and
AST  2.5 upper limit of normal. No prior therapy with chemotherapy,
erlotinib, or other agents targeting the EGFR pathway was allowed; radiation
therapy and major surgery had to be completed  3 weeks before enrollment.
Patients with brain metastases were required to be  3 weeks from completion
of radiation therapy and asymptomatic and could not be receiving corticoste-
roid therapy. Patients with NSCLC not otherwise specified or those whose
pathology consisted of only a fine needle aspirate were not eligible. This trial
was approved by the institutional reviews boards of the participating institu-
tions, and patients were required to provide informed consent before enroll-
ment. This trial was registered with ClinicalTrials.gov.
Treatment
Patients were randomly assigned to erlotinib 150 mg daily alone (arm A)
or erlotinib 150 mg daily continuous in combination with paclitaxel 200
mg/m2 every 21 days and carboplatin area under the curve of 6 using the
Calvert formula every 21 days (arm B) for up to six cycles; patients assigned to
arm B continued to receive erlotinib after completion of chemotherapy.9
Patients in both arms continued to receive erlotinib until disease progression
or unacceptable toxicity. One cycle was defined as 21 days in both arms. Dose
reductions for erlotinib were to 100 mg and 50 mg daily; one dose-level
reduction was performed for grade 3 rash or diarrhea and grade  2 conjunc-
tivitis. Erlotinib was discontinued for interstitial pneumonitis, grade 4 diarrhea
or rash, and grade  2 keratitis. Patients in arm B were required to have an
absolute neutrophil count  1,500/mL and platelets  100,000/mL on day 1 of
each cycle; treatment could be delayed up to 2 weeks. Standard dose reductions
were used for paclitaxel and carboplatin. Patients developing toxicity with
paclitaxel and/or carboplatin had the option to continue one of the chemo-
therapy agents alone along with erlotinib or with erlotinib alone. Management
of rash, diarrhea, supportive care, and antiemetics was at the discretion of the
treating physician.
Trial Design and Statistical Considerations
The primary objective was to estimate progression-free survival (PFS) in
each arm; secondary objectives included overall RR (ORR), OS, toxicity, and
determination of PFS in patients with and without EGFR mutations in each
arm. A total of 180 eligible patients (arm A, 80; arm B, 100) were to be accrued.
Sample size was determined to have adequate power to address the primary
objective. For arm A, it was prespecified that if median PFS were  2.9 months,
it would not be of further interest; if median PFS were  4.3 months, it would
be worthy of further investigation. Assuming constant hazards, it was equiva-
lent to test H0: 18-week PFS  37% v H1: 18-week PFS  52% for arm A. For
arm B, it was determined that if treatment were associated with median PFS
 4.0 months, it would not be of further interest; if median PFS were  6.0
months, the regimen would be worthy of further investigation. Assuming
constant hazards, it was equivalent to test H0: 18-week PFS  49% v H1:
18-week PFS  62% for arm B. The size of arms A and B allowed the testing of
each hypothesis at a one-sided significance level of .10 with approximately 90%
power. This trial was not designed to have adequate power to compare the
efficacy of the two arms.
The expected frequency of EGFR mutations in this patient population
was 15%. It was assumed that the RRs for EGFR–wild-type and -mutant
patients were 10% and 60% in arm A, respectively. With 80 patients in arm A,
there was 96% power to detect a 50% increase in RR between EGFR–wild-type
and -mutant patients, at a significance level of .05 with a two-sided 2 test.
With 76 events, the study had 95% power, at a significance level of .05 using a
two-sided log-rank test, to detect an HR of 0.31 (3 v 9.5 months) for PFS in
favor of EGFR-mutant patients. In arm B, it was assumed that the RRs were
25% and 75% for EGFR–wild-type and -mutant patients, respectively. With
100 patients, there was 97% power to detect a 50% increase in RR between
EGFR–wild-type and -mutant patients, at a significance level of .05 with a
two-sided 2 test. With 89 events, the study had 83% power, at a significance
level of .05 using a two-sided log-rank test, to detect an HR of 0.42 (5 v 12
months) for PFS in favor of EGFR-mutant patients.
PFS was defined as the time between random assignment and disease
progression or death (whichever occurred first); OS was defined as the time
from random assignment until death resulting from any cause. Kaplan-Meier
product limit estimator was used to estimate median PFS and OS as well as
95% CIs.10 The proportion of patients who experienced a response (partial or
complete) and the exact 95% CI were estimated. Rates of treatment-related
adverse events by type between arms were compared by Fisher’s exact test. All
P values are two sided.
EGFR Mutation Analysis
EGFR mutations were performed at the Dana-Farber Cancer Institute
(Boston, MA) using a sensitive heteroduplex method coupled with enzymatic
digestion as previously described.11 All positive findings were independently
verified and subjected to sequencing. The mutation analyses were blinded to
the patients’ clinical outcome.
On-Study Assessment
Patients were required to undergo history and physical examination,
tumor measurements, complete blood count, and serum chemistries at base-
line. Patients underwent computed tomography of the chest and abdomen
including the liver and adrenals, bone scan, and computed tomography or
magnetic resonance imaging of the brain before registration. Patients under-
went reimaging every two cycles (6 weeks) until disease progression or unac-
ceptable toxicity. Patients were evaluated every cycle (3 weeks) via history and
physical examination, complete blood count, and serum chemistries, and
toxicity was assessed using the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 3.0.
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RESULTS
Patient Characteristics and Treatment Administration
Between August 2005 and April 2009, 188 patients were enrolled;
seven patients withdrew consent before initiating study therapy; 81
patients in arm A and 100 in arm B received study therapy (Fig 1). A
majority of the patients were female (59%), were white (80%), had a
performance score of 0 (54%), were never smokers (79%), and had
adenocarcinoma histology (86%; Table 1). The median number of
cycles of erlotinib in arm A was six (range, one to 70). The median
number of cycles of therapy in arm B was eight (range, one to 70); the
median number of cycles of the combination of erlotinib, carboplatin,
and paclitaxel was three (range, one to six). Twenty-seven percent (48
of 181) of patients (arm A, 28%; arm B, 25%) received  18 cycles (1
year) of therapy.
Toxicity
In arm A, 23% of patients had a dose reduction in at least one
cycle. In arm B, 27% of patients had a dose reduction in at least one
cycle. The most common reason for treatment discontinuation in
both arms was progressive disease: 61 patients (75%) in arm A and 71
patients (71%) in arm B. The rates of grades 3 to 4 hematologic toxicity
were significantly higher (49% v 2%; P  .001) in arm B compared
with arm A (Table 2). Similarly, the rates of nonhematologic toxicity
(52% v 24%; P  .001) were greater in arm B compared with arm A.
The rate of grade 3 acne/acneiform rash was similar in arms A and B
(Table 2). Two patients in arm B experienced treatment-related death,
one patient as a result of renal failure and one as a result of an adverse
event not associated with a CTCAE term.
Efficacy
Median follow-up for all patients was 38 months, and all 181
patients were evaluable for PFS and OS. In the treated patient popu-
lation, the ORR in arm A was 35% (95% CI, 24 to 46; n  28), and 28
patients (35%) experienced stable disease; median PFS and OS were
5.0 (95% CI, 2.9 to 7.0) and 24.6 months (95% CI, 18.4 to 33.8),
respectively (Fig 2A). In arm B, the ORR was 46% (95% CI, 36 to 56;
n46), and 38 patients (38%) experienced stable disease; median PFS
Reasons for discontinuation
  Progressive disease (n = 71; 71%)
  Adverse event (n = 7; 7%)
)%2 ;2 = n( htaeD  
  Withdrew consent (n = 4; 4%)
  Initiated other therapy (n = 3; 3%)
  Other reason (n = 4; 4%)
Still on treatment (n = 9; 9%)
Reasons for discontinuation
  Progressive disease (n = 61; 75%)
  Adverse event (n = 3; 4%)
)%4 ;3 = n( htaeD  
  Withdrew consent (n = 1; 1%)
  Other medical illness (n = 1; 1%)
  Initiated other therapy (n = 3; 4%)
  Other reason (n = 2; 2%)









Withdrew consent prior to
initiating chemotherapy
(n = 7)
Fig 1. CONSORT diagram showing pa-
tient disposition.








No. % No. % No. %
No. of patients 81 100 181
Age, years
Median 58 60 59
Range 32-78 34-81 32-81
Sex
Male 32 40 42 42 74 41
Female 49 60 58 58 107 59
Ethnicity
White 61 75 84 84 145 80
African American 12 15 6 6 18 10
Asian 5 6 8 8 13 7
Other 2 3 1 1 3 2
Unknown 1 1 1 1 2 1
ECOG performance status
0 50 62 48 48 98 54
1 31 38 52 52 83 46
Smoking history
Never smoker 64 79 79 79 143 79
Light former smoker 17 21 21 21 38 21
Histology
Adenocarcinoma 71 88 84 84 155 86
Bronhioloalveolar cancer 2 2 2 2 4 2
Adenocarcinoma with
bronchioloalveolar features 8 10 14 14 22 12
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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and OS were 6.6 (95% CI, 5.4 to 8.2) and OS 19.8 months (95% CI,
14.4 to 27.8), respectively (Fig 2B). The primary end point was met in
both arms of the study. The 18-week PFS rate for arm A was 52% (80%
CI, 45 to 59); the lower limit of the 80% CI is above the prespecified
limit of no interest in H0 ( 37%). Similarly, the 18-week PFS rate for
arm B was 69% (80% CI, 62 to 74), and the lower limit of the 80% CI
is above the prespecified limit of no interest in H0 ( 49%).
Efficacy in EGFR-Mutant and Wild-Type Patients
EGFR mutation analysis was successfully performed in 164 pa-
tients (91%); 17 patients had insufficient material or DNA for analysis
(demographics listed in Appendix Table A1, online only). The muta-
tional analysis was successfully performed in 77 (95%) of 81 patients in
arm A and 87 (87%) of 100 patients in arm B. EGFR-activating drug-
sensitive mutations, deletions of exon 19, and L858R point mutations
were detected in 33 patients (43%) in arm A and 33 patients (38%) in
arm B. In arm A, exons 19 and 21 mutations were detected in 23 and 10
tumor respectively; in Arm B exon 19 and 21 mutations were detected
in 16 and 17 tumors, respectively. Six patients had EGFR exon 20
insertion mutations associated with erlotinib resistance (Appendix
Table A2, online only).12 The outcome analyses were limited to pa-
tients with exon 19 deletions and L858R mutations to compare find-
ings from the current study with those of prospective clinical trials
limited to exons 19 and 21 EGFR-mutant patients with NSCLC.13-15
The frequency of EGFR mutations in never smokers (40%; 51 of 128)
was similar (P  .84) to the frequency in former light smokers (42%;
15 of 36), consistent with prior observations.16 In both arms, the ORR
was significantly greater (P  .001) for patients with EGFR-mutant
tumors (Table 3). Similarly, median PFS and OS were significantly
longer for patients with EGFR-mutant tumors compared with those
with EGFR–wild-type tumors in both arms of the study (Table 3; Figs
3A to 3D). PFS and OS for EGFR-mutant patients were similar in both
arms of the study (Table 3; Appendix Fig A1, online only).
We also analyzed the outcome of patients based on the specific
EGFR mutation (exon 19 deletion v L858R). Patients with EGFR exon
19 deletion mutations had a significantly greater RR to erlotinib (83%
v 40%; P  .0349) compared with those with L858R mutations (Ap-
pendix Table A3, online only). PFS was numerically longer for patients
with EGFR exon 19 mutations treated in either arm A or B compared
with those with L858R mutations (Appendix Table A3). OS was sim-
ilar for patients with EGFR exon 19 deletions and L858R tumors
(Appendix Table A3).
DISCUSSION
Patients with NSCLC whose tumors harbor EGFR mutations derive
the greatest degree of benefit from first-line EGFR TKI therapy.6
These observations have been validated in retrospective and prospec-
tive clinical trials, and currently EGFR TKIs are commonly used as
first-line therapy for advanced EGFR-mutant NSCLC.6,13,15,17 Our
findings are consistent with prior observations. The outcome (RR and
BA
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Fig 2. (A) Progression-free survival and (B) overall survival in all patients. E; erlotinib, ECP; erlotinib plus carboplatin and paclitaxel.







Grade 3 Grade 4 Grade 3 Grade 4
No. % No. % No. % No. %
Hematologic
Anemia 1 1 0 0 7 7 0 0 .0763
Febrile neutropenia 0 0 0 0 9 9 3 3  .001
Neutropenia 0 0 0 0 24 24 17 17  .001
Thrombocytopenia 0 0 0 0 1 1 4 4 .0659
Maximum 2 2 0 0 29 29 20 20  .001
Nonhematologic
Allergic reaction
(hypersensitivity) 0 0 0 0 4 4 0 0 .1291
Diarrhea 4 5 0 0 7 7 0 0 .7567
Fatigue 1 1 0 0 16 16 1 1  .001
Nausea 1 1 0 0 7 7 0 0 .0763
Neuropathy (sensory) 0 0 0 0 6 6 0 0 .0338
Rash (acne/acneiform) 6 7 0 0 10 10 0 0 .6068
Vomiting 1 1 0 0 7 7 0 0 .0763
Maximum 18 22 2 2 39 39 13 13  .001
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PFS) of patients with EGFR mutations treated with erlotinib alone
(arm A) was similar to that in other prospective studies, in both white
and Asian patients, of erlotinib in treatment-naive EGFR-mutant pa-
tients.15,18 The poor PFS in the EGFR–wild-type patients treated with
erlotinib alone was also similar to that in prior studies of EGFR inhib-
itors in EGFR–wild-type patients or in those clinically unlikely to
harbor an EGFR mutation.6,19 The current study further reinforces the
importance of molecular rather than phenotypic selection of patients
for first-line EGFR TKI therapy.6,18 This is particularly important for
white patients, in whom, even in this highly clinically enriched patient





EGFR Mutant EGFR WT P  EGFR Mutant EGFR WT P 
No. of patients 33 44 33 54
ORR, % 70 9  .001† 73 30  .001†
95% CI 51 to 84 3 to 22 18 to 44 18 to 44
PFS, months  .001‡  .001‡
Median 14.1 2.6 17.2 4.8
95% CI 7.0 to 19.6 1.4 to 3.9 8.2 to 28.7 2.8 to 5.6
OS, months .0198‡ .0011‡
Median 31.3 18.1 38.1 14.4
95% CI 23.8 to NA 9.5 to 27.8 19.6 to NA 8.7 to 20.2
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HR, 0.33; 95% CI, 0.20 to 0.54
Log-rank P < .001
HR, 0.27; 95% CI, 0.16 to 0.45
Log-rank P < .001
HR, 0.40; 95% CI, 0.23 to 0.71
Log-rank P = .0011
HR, 0.50; 95% CI, 0.28 to 0.91
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EGFR mut (n = 33)
EGFR WT (n = 54)
Fig 3. (A) Progression-free (PFS) and (B) overall survival (OS) based on EGFR mutation (mut) in arm A (erlotinib alone). (C) PFS and (D) OS based on EGFR mut in arm
B (erlotinib plus carboplatin and paclitaxel). HR, hazard ratio; WT, wild type.
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population, the frequency of EGFR mutations was only 40% com-
pared with 60% in Asian patients with similar phenotypes.6 Clinical
trials have demonstrated that in unselected white patients who are
unlikely to have EGFR-mutant tumors, first-line erlotinib therapy is
associated with a survival detriment when compared with platinum-
based chemotherapy.19,20
An important unresolved issue that in part led to the design of
this trial was whether in the population of patients most sensitive to
erlotinib (ie, EGFR-mutant patients) there would be any additional
clinical benefit with the addition of systemic chemotherapy. Our find-
ings would suggest that there is little, if any, such benefit (as measured
by RR and PFS) in combining chemotherapy with erlotinib compared
with erlotinib alone in EGFR-mutant patients (Table 3; Appendix Fig
A1, online only). However, these findings should not be considered
definitive, because the two-arm phase II trial was not designed to make
formal comparison of these end points between the regimens. Our
study, using continuous erlotinib therapy, also does not support the
notion that EGFR TKIs and chemotherapy are antagonistic with one
another.21 In fact, even among EGFR–wild-type patients, in both
arms, OS was longer than OS observed in recent phase III trials.22,23 A
randomized phase II trial conducted in Asia using intermittent erlo-
tinib with chemotherapy demonstrated significantly longer PFS com-
pared with chemotherapy alone.24 However, this study did not include
an erlotinib-only arm or detailed molecular analyses on the majority
of patients to determine whether a similar outcome would have been
observed with single-agent erlotinib therapy.24 Intriguingly, the
findings from EGFR-mutant NSCLC are in contrast with those in
HER2-amplified breast cancer, in which, although trastuzumab has
single-agent activity, the majority of the clinical benefit is derived from
the combination of trastuzumab with chemotherapy.25,26
Improving PFS of patients with EGFR-mutant NSCLC treated
with erlotinib remains a critical therapeutic challenge. Our study sug-
gests that this is unlikely to be achieved by adding chemotherapy to
erlotinib. Current studies are evaluating the benefit of the addition of
bevacizumab to erlotinib in EGFR-mutant NSCLC based on a subset
analysis of a prior clinical trial.27 Additional efforts aimed at under-
standing the biology of EGFR-mutant NSCLC and/or the develop-
ment of more effective EGFR-targeted therapies are necessary to
improve the outcome of patients with EGFR-mutant NSCLC.28,29
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